Emcure Pharmaceuticals – Q4 FY26 Results

key financial highlights

• Revenue from Operations:
  • Total Income (Q4 FY26): ₹24,697.03 Million
    • QoQ Change: +4.49%
    • YoY Change: +16.70%
  • Previous Quarter (Q3 FY26): ₹23,634.78 Million
  • Previous Year (Q4 FY25): ₹21,162.45 Million
• Profit After Tax (PAT):
  • PAT (Q4 FY26): ₹2,437.36 Million
    • QoQ Change: +5.34%
    • YoY Change: +23.57%
  • Previous Quarter (Q3 FY26): ₹2,313.70 Million
  • Previous Year (Q4 FY25): ₹1,972.37 Million
• QoQ Performance
  • Revenue Trend: Moderate Growth
  • Profit Trend: Stable Growth

Margin Analysis

Drivers:

• Increase in employee benefit expenses
• Higher other operating expenses
• Inventory adjustments impacting cost structure
• Exceptional item impact in current quarter

Insight:

• Revenue growth is strong, but margin expansion is limited due to rising operational costs

Earning quality check

Drivers:

• Strong core operating revenue growth
• Impact of exceptional items (negative in current quarter)
• Increase in depreciation and finance costs
• Forex gains partially supporting earnings

Interpretations:

• Earnings quality is moderate — growth is driven by operations, but profitability is influenced by one-offs and cost pressures

balance sheet Analysis

• Total Assets: ₹96,124.81 Mn
• Total Liabilities: ₹46,358.08 Mn

Insight:

• The company shows asset expansion with a noticeable increase in current liabilities, indicating working capital intensity and possible leverage increase

key risks

• Rising operating costs impacting margins
• Increasing short-term borrowings
• High working capital requirements
• Dependence on inventory and receivables cycle

management strategy signals

Focus Area:

• Capacity expansion through capital expenditure
• Investment in intangible assets and product development
• Strengthening domestic and export markets
• Managing working capital cycle

Financial metrics table

Quarterly Performance Context